Other safety alerts
|
| |
| US FDA issues early communication about ongoing safety review of weight loss drug orlistat |
| |
The U.S. Food and Drug Administration announced that it is reviewing adverse event reports of liver injury in patients taking the weight loss drug orlistat, marketed as Xenical and Alli. The FDA’s analysis of these data is ongoing, and no definite association between liver injury and orlistat has been established at this time. The FDA will release its findings on orlistat as soon as the review is completed. The relevant link for the news is:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm180057.htm
Situation in Hong Kong: Xenical is registered by Roche Hong Kong Ltd in HK. Any new findings about orlistat will be kept in view.
Ends/Tuesday, August 25, 2009
Issued at HKT 16:00
|
| |
|
